LEDGF/p75-Independent HIV-1 Replication Demonstrates a Role for HRP-2 and Remains Sensitive to Inhibition by LEDGINs by Schrijvers, Rik et al.
LEDGF/p75-Independent HIV-1 Replication
Demonstrates a Role for HRP-2 and Remains Sensitive to
Inhibition by LEDGINs
Rik Schrijvers
1, Jan De Rijck
1, Jonas Demeulemeester
1, Noritaka Adachi
2, Sofie Vets
1, Keshet Ronen
3,
Frauke Christ
1, Frederic D. Bushman
3, Zeger Debyser
1"*, Rik Gijsbers
1"*
1Division of Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Flanders, Belgium, 2Graduate School of Nanobioscience, Yokohama City University, Yokohama,
Japan, 3Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
Abstract
Lens epithelium–derived growth factor (LEDGF/p75) is a cellular cofactor of HIV-1 integrase (IN) that interacts with IN
through its IN binding domain (IBD) and tethers the viral pre-integration complex to the host cell chromatin. Here we report
the generation of a human somatic LEDGF/p75 knockout cell line that allows the study of spreading HIV-1 infection in the
absence of LEDGF/p75. By homologous recombination the exons encoding the LEDGF/p75 IBD (exons 11 to 14) were
knocked out. In the absence of LEDGF/p75 replication of laboratory HIV-1 strains was severely delayed while clinical HIV-1
isolates were replication-defective. The residual replication was predominantly mediated by the Hepatoma-derived growth
factor related protein 2 (HRP-2), the only cellular protein besides LEDGF/p75 that contains an IBD. Importantly, the recently
described IN-LEDGF/p75 inhibitors (LEDGINs) remained active even in the absence of LEDGF/p75 by blocking the interaction
with the IBD of HRP-2. These results further support the potential of LEDGINs as allosteric integrase inhibitors.
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Introduction
Integration of viral DNA into the host cell genome is a critical
step during HIV replication. A stably inserted provirus is essential
for productive infection and archives the genetic information of
HIV in the host cell. The presence of a permanent viral reservoir
that evades the immune system and enables HIV to rebound once
antiretroviral drugs are withdrawn is one of the major remaining
hurdles to surmount the HIV epidemic.
Lentiviral integration is catalyzed by the viral enzyme IN in
close association with the cellular cofactor LEDGF/p75 [1–7].
LEDGF is encoded by the PSIP1 gene, which generates the splice
variants LEDGF/p52 and LEDGF/p75 [8]. Both share an N-
terminal region of 325 residues containing an ensemble of
chromatin binding elements, such as the PWWP and AT hook
domain, yet differ at the C-terminus. LEDGF/p52 contains 8
amino acids at its C-terminus [9] and fails to interact with HIV-1
IN [10,11], whereas LEDGF/p75 contains an IBD (aa 347–429)
capable of interacting with lentiviral IN [3,12,13]. The cofactor
tethers IN to the host cell chromatin, protects it from proteolytic
degradation, stimulates its enzymatic activity in vitro and in living
cells [1,10,13–16] and determines HIV-1 integration site distri-
bution [2,11,17,18].
The role of LEDGF/p75 in HIV-1 replication was studied using
RNA interference (RNAi) targeting LEDGF/p75 or using LEDGF
KO murine embryonic fibroblasts (MEF) [2,5,6,11,17,19,20].
Although both strategies point to a key role for LEDGF/p75 in
lentiviral replication, they resulted in somewhat conflicting
conclusions. Potent RNAi-mediated knockdown (KD) of
LEDGF/p75 reduced HIV-1 replication, yet residual replication
was observed [5,6,20], which was attributed to imperfect RNAi-
mediated KD of LEDGF/p75, with minute amounts of LEDGF/
p75 being sufficient to support HIV-1 replication [5,6]. Whether
LEDGF/p75 is essential for HIV-1 replication or not could not be
addressed by this approach. Later, two LEDGF KO mice were
generated. Since mouse cells are not permissive to spreading HIV-
1 infection, HIV-based viral vectors were used. The first effort
resulted in mouse LEDGF KO clones following insertion of a gene
trap [21]. Data obtained from MEFs isolated from these embryos
indicated a strong yet incomplete block in integration of HIV-
based lentiviral vectors (LV) [17]. Next, a Cre-conditional LEDGF
KO mouse was generated. Challenge of the KO MEFs with LV
resulted in reduced but not annihilated reporter gene expression
[11]. Although analysis was restricted to single round assays, both
studies suggest LEDGF/p75 not to be essential for HIV-1
replication, with the cofactor being involved in integration site
selection rather than in promoting integration. Here we present
the generation of the first human somatic LEDGF/p75 KO cell
line to finally answer the question whether LEDGF/p75 is
required for spreading infection of various HIV strains.
PLoS Pathogens | www.plospathogens.org 1 March 2012 | Volume 8 | Issue 3 | e1002558Besides LEDGF/p75, a second member of the hepatoma-
derived growth factor related protein family [22], Hepatoma-
derived growth factor related protein 2 (HRP-2), was shown to
interact with HIV-1 IN [12]. Although HRP-2 overexpression
relocated IN from the cytoplasm to the nucleus in LEDGF/p75-
depleted cells [23], the IN–HRP-2 interaction was weaker than the
IN-LEDGF/p75 interaction [12]. Neither transient [20,24] nor
stable HRP-2 KD [6] reduced HIV-1 replication even after
reduction of LEDGF/p75, suggesting that HRP-2 is not involved
in HIV replication. However, it has not been excluded that in the
absence of LEDGF/p75 HRP-2 can function as an alternative
molecular tether of HIV integration.
Allosteric HIV-1 IN inhibitors that target the LEDGF/p75-IN
interaction interface (LEDGINs) and potently block HIV-1
replication [25] are in preclinical development. The existence of
alternative cellular cofactors, such as HRP-2, or alternative escape
routes might hamper the clinical development of this class of
compounds. To answer these questions, we have generated a
human somatic LEDGF/p75 KO cell line. We demonstrate that
laboratory-adapted HIV strains are capable of replicating in the
absence of LEDGF/p75 but show a drastic replication defect. We
show that this residual replication in the absence of LEDGF/p75
is predominantly mediated by HRP-2. Finally, we demonstrate
that LEDGINs remained fully active even in the absence of
LEDGF/p75 corroborating their allosteric mechanism of action.
Results
Generation of a human somatic LEDGF/p75 KO cell line
To clarify the role of LEDGF/p75 during spreading HIV-1
infection, we generated a human somatic KO in Nalm-6 cells, a
human pre-B acute lymphoblastic leukemia cell line [26,27]. We
eliminated the LEDGF/p75 isoform while preserving the LEDGF/
p52 splice variant. Deletion of exon 11 to 14 in the PSIP1 gene fuses
exon 10 to exon 15 resulting in a frame shift that yields a truncated
LEDGF/p75 in which the C-terminus, including the IBD (aa 326–
530) is replaced by a 9 aa tail (Figure S1A, referred to as
LEDGF
KO). Targeting plasmids were designed carrying the
genomic flanking regions of LEDGF/p75 exon 11 and 14,
interspersed with a floxed selection cassette (Figure 1A). Following
transfection of wild-type Nalm-6 cells (Nalm
+/+) with the first
targeting plasmid and subsequent selection, three heterozygous
clones (cl) (denoted as Nalm
+/c; cl 31, cl 97 and cl 147, respectively)
were obtained (Figure 1B). We continued with Nalm
+/c cl 31.
Transfection of Nalm
+/c cl 31 with the second targeting plasmid
resulted in the selection of a homozygous KO clone carrying both
resistance cassettes (Nalm
c/c 31 cl 73). Selection cassettes were
removed by Cre-mediated excision, resulting in seven LEDGF/p75
KO clones, referred to as Nalm
2/2 cl 1-7.
Correct homologous recombination of the genomic region was
verified via genomic PCR (Figure 1C), Southern blot analysis
(Figure 1D) and sequencing of the genomic and mRNA region
(Figure S1A). The absence of wild-type LEDGF/p75 in the KO
cells was corroborated by RT-PCR (Figure S1B and S1C), qRT-
PCR (Figure S1D) and Western blot analysis (Figure 1E, arrow). A
band of 52 kDa appears in the Nalm
+/c and Nalm
2/2 cell lines; it
corresponds to the truncated form, LEDGF
KO (Figure 1E,
arrowhead), and is absent in wild-type cells. Throughout the
manuscript Nalm
2/2 cl 1 and cl 2 monoclonal cell lines are used.
Wild-type Nalm-6 cells, referred to as Nalm
+/+, were used as
controls, next to Nalm
+/c cl 31, referred to as Nalm
+/c, the closest
clonal ancestor of the Nalm
2/2 cells.
Single round lentiviral transduction of LEDGF/p75 KO
cells is hampered at the integration step
WefirstevaluatedwhethertheLEDGF/p75KOcells(Nalm
2/2)
support transduction by a single round HIV-based viral vector. We
challenged the abovementioned engineered cell lines with a VSV-G
pseudotyped HIV reporter virus encoding firefly luciferase under
control of the viral long terminal repeat promoter (HIV-fLuc).
Transduction efficiency (RLU/mg protein) was 6.7-fold lower in
Nalm
2/2 cells (cl 1 and cl 2) compared to control Nalm
+/+ and
Nalm
+/c cells (Figure 1F) (1563.7% residual reporter activity;
n=10). Quantitative PCR revealed 2.4-fold lower integrated copies
comparing Nalm
2/2 with Nalm
+/c (Figure 1G), whereas late RT
products (Figure S1E) and 2-LTR circles remained unaffected
(Figure S1F). Together these data indicate a block between reverse
transcription and integration.
Since LEDGF/p75 determines lentiviral integration site
selection, we analyzed the distribution of HIV-1 integration sites
in the absence of LEDGF/p75. A total of 2535 HIV-1 integration
sites were obtained in Nalm-6 cells of which 799 in Nalm
2/2
(Table 1). Random control sites were generated computationally
and matched to experimental sites with respect to the distance to
the nearest MseI cleavage site (matched random control, MRC)
[2]. LEDGF/p75 KO significantly reduced the preference of
HIV-1 to integrate in RefSeq genes (P,0.0001 for comparison of
Nalm
2/2 cl 1 or 2 with Nalm
+/+ or Nalm
+/c) and instead, a
preference for CpG islands (P,0.05 for comparison of Nalm
2/2
cl 1 or 2 with Nalm
+/+ or Nalm
+/c and P,0.0001 for pooled
comparison) emerged (Figure 1H and Table 1). Similar results
were obtained using the Ensembl and UniGene annotation (Figure
S1G and S1H). HIV-1 integration events in RefSeq genes
remained nevertheless significantly favored over MRC in the
KO cells (P,0.0001). The target DNA consensus proved to be
LEDGF/p75 independent (compare Figure S1I with S1J). The
consensus sequence for the different cell lines was similar to that
determined previously [28–30].
In LEDGF/p75 KO cells residual replication is observed
with laboratory strains but not with clinical isolates of
HIV-1
In human LEDGF/p75 KD cells HIV-1 replication is
hampered, but not completely blocked which can be attributed
Author Summary
Like other viruses, HIV has a limited genome and needs to
exploit the machinery of the host cell to complete its
replication cycle. The elucidation of virus-host interactions
not only sheds light on pathogenesis but also provides
opportunities in a limited number of cases to develop
novel antiviral drugs. A prototypical example is the
interaction between the cellular protein LEDGF/p75 and
HIV-1 integrase (IN). Here we generated a human somatic
LEDGF/p75 knockout cell line to demonstrate that HIV-1
replication is highly dependent on its cofactor. We show
that the residual replication of laboratory strains is
predominantly mediated by a LEDGF/p75-related protein,
HRP-2. Interestingly, the recently developed HIV-1 IN
inhibitors that target the LEDGF/p75-IN interaction inter-
face, LEDGINs, remain active even in the absence of
LEDGF/p75. We demonstrate that LEDGINs efficiently block
the interaction between IN and HRP-2. In case HIV-1 would
be able to bypass LEDGF/p75-dependent replication using
HRP-2 as an alternative tether, LEDGINs would remain fully
active.
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Although single round viral vector transduction was severely
reduced in LEDGF KO MEFs [11,17,21], spreading HIV-1
infection in the absence of LEDGF/p75 could not be tested. To
test HIV-1 replication, we introduced the CD4 receptor into the
Nalm-6 cells that express CXCR4 [31], a co-receptor for HIV-1
Figure 1. Generation and validation of human LEDGF/p75 KO cell line. (A) Scheme for PSIP1 gene targeting by homologous recombination.
The 2.3 and 2.0 kb arm indicated on the targeting plasmids enable homologous recombination and harbor a puromycin (Puro
r) or hygromycin B
resistance (Hyg
r) cassette (c) flanked by loxP sites (arrows). Exon 11 of p52 and p75 are indicated separately as well as the IBD coding region. BamHI
restriction sites are indicated (scissors). DT-A denotes the gene encoding for Diphteria toxin A. (B) Schematic overview of KO and intermediates: Nalm-
6 wild-type (Nalm
+/+) contains 2 PSIP1 genes; Nalm
+/c clones (cl) 31, 97, 147, contain a puromycin resistance cassette in one allele; Nalm
c/c 31 cl 73,
contains both a puromycin and a hygromycin B resistance cassette; after CRE-mediated excision cl 1-7 are generated and termed Nalm
2/2. (C)
Genomic PCR on DNA from different clones. Primer binding sites are indicated in panel A (see also Table S2). Indicated bands confirm amplification of
a 1.6 kb fragment by primers D and E in full length PSIP1 as shown in Nalm
+/c and Nalm
+/+, but not in Nalm
c/c and Nalm
2/2 cl 1. (D) Southern blot on
genomic DNA after BamHI digestion. Probe and restriction sites are indicated in panel A. Intact PSIP1 generates a 16.2 kb fragment. After insertion of
a resistance cassette a 7.5 kb fragment is generated, after CRE-mediated excision a 14.6 kb fragment is formed indicating KO of a 1.6 kb fragment
containing exon 11–14. (E) Western blot analysis for LEDGF protein of whole cell extracts. Marker heights (right), LEDGF/p75 (arrow) and LEDGF
KO
(arrowhead) are indicated. (F) Nalm-6 cells were transduced with HIV-fLuc. Luciferase expression is shown as percentage relative light units (RLU) per
mg protein as compared to Nalm
+/c cl 31. (G) In parallel, the number of integrated proviral copies was evaluated for HIV-fLuc. Following transduction,
cells were grown for at least 10 days to eliminate non-integrated viral DNA and analyzed by quantitative PCR. (H) HIV-1 integration site distribution
analysis. Left panel shows relative number of experimentally derived HIV-1 integration events in genes according to the RefSeq annotation, versus
computationally generated matched random control (MRC). The right panel shows integration events occurring 62 kb around CpG islands as
compared with MRC. Average 6 standard deviations are shown from experiments performed at least in triplicate.
doi:10.1371/journal.ppat.1002558.g001
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+/+, Nalm
+/c
and Nalm
2/2 cl 1 and cl 2) showed similar growth rates (Figure
S6A and S6C) and CD4 and CXCR4 expression levels (Figure
S6D and S6E). We then challenged the respective cell lines with
the laboratory strain HIVNL4.3 (Figure 2A). Both Nalm
+/+ (Figure
S2A) and Nalm
+/c cells supported viral replication to the same
extent (Figure 2A). Peak viral replication was consistently observed
between day 7 and 9 post infection depending on the multiplicity
of infection (MOI; compare MOI 0.5 and 0.1 in Figure 2A). In
Nalm
2/2 cells infected with HIVNL4.3, low-level p24 production
was observed, eventually leading to a breakthrough albeit after a
lag-period of 14 to 18 days compared to control cells (Figure 2A,
n=6, a representative experiment is shown). Comparable data
showing this delay were obtained with another laboratory strain,
HIVIIIb (data not shown).
Next, we challenged the different cell lines with two clinical
isolates of HIV-1 (93TH053, denoted as #1 and 96USSN20 [32],
denoted as #2). Viral breakthrough was observed 17 to 20 days
post infection in the control cell line (Figure 2B and 2C). In the
first two weeks after infection of the KO cell lines only a discrete
increase in p24 was observed; at 35 days after infection p24 levels
were below detection limit (Figure 2B and 2C).
Residual virus production in KO cells is caused by
spreading infection which is hampered at the integration
step
We next evaluated whether the rise in p24 titers observed in
Nalm
2/2 cells after challenge with laboratory HIV-1 strains could
be explained by virus release from cells infected in the first round,
rather than ongoing replication cycles. Therefore we challenged
Nalm
+/c and Nalm
2/2 cells with HIVNL4.3 and resuspended the
cells at 8 hrs post infection (Figure S2B) in fresh medium
containing either zidovudine (AZT), ritonavir (RIT) or no
inhibitor. AZT, a reverse transcriptase inhibitor, blocks infection
of new cells but allows monitoring of virus release from already
infected cells whereas RIT, a protease inhibitor, blocks processing
of GAG-precursor processing in the virus released from infected
cells. In Nalm
2/2 cells as well as in control Nalm
+/c cells the p24
production clearly decreased in the presence RIT or AZT. The
decrease in p24 in Nalm
+/c without inhibitor at day 6 was due to
the cytopathic effect of the virus. This indicates that the p24
increase observed in Nalm
2/2 cells results from spreading
infection and not solely from virus release from cells infected in
the first round.
The observed delay in multiple round HIV-1 replication in the
absence of LEDGF/p75 was further analyzed by quantification of
the different HIV-1 DNA species at different time points after
infection. Late RT products at 10 hrs post infection and 2-LTR
circles at 24 hrs post infection were comparable in Nalm
+/c and
Nalm
2/2 cells (Figure S3A and S3B). Addition of the IN strand
transfer inhibitor (INSTI) raltegravir (RAL) in Nalm
+/c and
Nalm
2/2 cell lines resulted in a comparable increase in 2-LTR
circles at 24 hrs post infection. The number of integrated proviral
copies (Alu-qPCR,Figure S3C) was severely reduced in the presence
of RAL. In Nalm
2/2 a reduction in the number of integrants was
detected after 24 and 48 hrs compared to Nalm
+/c cell lines.
We next characterized the virus harvested from Nalm
2/2 at day
18 after infection with the laboratory strain HIVNL4.3 (referred to as
HIV
2/2). Challenging Nalm
+/c cells with this virus demonstrated
that HIV
2/2 is replication competent (Figure S2C, right panel,
HIV
2/2 on Nalm
+/c). In addition, we evaluated whether HIV
2/2
virus was phenotypically adapted to the absence of LEDGF/p75.
HIV
2/2 replication remained impaired in Nalm
2/2 compared to
Nalm
+/c cells(Figure S2C, rightpanel).TheproviralINsequence of
HIV
2/2 was unaltered compared with the consensus sequence of
HIVNL4.3 (data not shown). Control HIV harvested from Nalm
+/c
cells (denoted as HIV
+/c) demonstrated a phenotype that was
comparable to that of HIVNL4.3 (Figure S2C, left panel). Serial
passaging (N=10) of HIV-1 on LEDGF/p75 KO cells did not
result in phenotypic adaptation or changes in the proviral IN
sequence (data not shown).
HRP-2 KD inhibits residual HIV-1 replication in LEDGF/p75
KO cells
Although residual HIV-1 replication in KO cells was only
detectable after infection with laboratory strains, we performed
additional experiments to understand this phenotype. Residual
viral replication in the absence of LEDGF/p75 can either be
explained by cofactor independent replication, or by the presence
of a second cofactor that substitutes for LEDGF/p75. Like
LEDGF/p75, HRP-2 also harbors a PWWP-domain and an IBD-
like domain shown to interact with HIV-1 IN in vitro [12]. In order
to determine whether HRP-2 can act as an alternative co-factor for
HIV integration, we targeted the HRP-2 mRNA using miRNA-
based short hairpins (miR HRP-2). As controls we employed a
vector lacking the miRNA expression cassette (denoted as control)
(Figure S7B). We generated stable HRP-2 KD cells, termed
Nalm
+/+
miR HRP-2, Nalm
+/c
miR HRP-2 and Nalm
2/2
miR HRP-2 and
matched controls Nalm
+/+
control, Nalm
+/c
control and Nalm
2/2
control.
HRP-2 KD cells showed 65, 75 and 80% depletion of HRP-2,
respectively, as determined by qPCR (Figure 3A). No effect on
cellular growth kinetics was observed (data not shown). Upon single
round transduction with HIV-fLuc no difference was observed in
Nalm
+/c cells with or without HRP-2 KD (Figure 3B, left panel),
whereas luciferase activity was reduced 5-fold in the Nalm
2/2
control
cell line (20.061.5%, n=3) dueto LEDGF/p75 KO.An additional
2.4-fold reduction was observed in Nalm
2/2
miR HRP-2 when
compared to Nalm
2/2
control (8.460.6%, n=3) (Figure 3B, left
panel) that correlated with a 2-fold reduction in integrated copies
(Figure 3B, right panel).
We next challenged these cells with the laboratory strain
HIVNL4.3 at different MOI (Figure 3C–E). In the control Nalm
+/+
and Nalm
+/c cell lines, we observed a minor reduction in viral
replication upon HRP-2 KD but only at lower MOI (compare
Figure 3C and 3D, E). However, HRP-2 KD in LEDGF/p75 KO
cells additionally inhibited HIV-1 replication 2- to 3-fold
Table 1. Integration frequency near mapped genomic
features in the human genome.
Cell line # sites
% in RefSeq
genes
%±2 kb CpG
islands
HIV sites Nalm
+/+ 1075 76.7** 4.2
Nalm
+/c 661 78.8** 5.0
Nalm
2/2 cl 1 404 52.2** 11.1**
Nalm
2/2 cl 2 395 51.4** 8.6**
MRC sites Nalm
+/+ 3225 39.8 2.8
(HIV) Nalm
+/c 1983 39.8 3.3
Nalm
2/2 cl 1 1212 40.8 3.6
Nalm
2/2 cl 2 1185 37.4 3.1
Abbreviations: MRC, matched random control.
Significant deviation from MRC using a two-tailed Fisher’s exact test (with
Bonferroni correction) is denoted by *P,0.00625,* * P,0.0001.
doi:10.1371/journal.ppat.1002558.t001
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2/2
control
and Nalm
2/2
miR HRP-2, detail panel). We generated a second
LEDGF/p75 KO HRP-2 KD cell line to corroborate our results.
Single round transduction with HIV-fLuc resulted in an additional
4.7-fold reduction of luciferase reporter activity when compared
with LEDGF KO cells (Figure S5F), whereas HIVNL4.3 replication
was affected 10-fold at day 8 post infection when comparing
LEDGF/p75 KO and LEDGF/p75 KO HRP-2 KD cells
(compare Figure S5D with S5E, condition without compounds).
To corroborate that additional KD of HRP-2 results in an
increased block of integration in LEDGF/p75 KO cells, we
analyzed the number of integrated viral copies at 24 hrs and at 5
days post infection, the latter in the presence of RIT (Figure 3F
and 3G, respectively). A 2-fold drop in proviral copies upon HRP-
2 KD was observed.
HRP-2 KD further hampers HIV-1 replication in LEDGF/
p75 KD cells
To extend our findings in LEDGF/p75 KO cells, we tested
whether HRP-2 KD resulted in additional reduction of viral
replication in LEDGF/p75 KD HeLaP4 (Figure S4), PM1
(Figure 4A–C) and SupT1 (Figure 4D–F) cell lines. First, wild-
Figure 2. Residual HIV-1 replication in LEDGF/p75 KO cells is only observed after challenge with laboratory strains. Control Nalm
+/c
and KO Nalm
2/2 cl 1 and cl 2 cell lines were challenged with the laboratory strain HIVNL4.3 (A) and clinical isolates #1, 93TH053 (B) and #2, 96USSN20
[32] (C). Cells were infected at different MOI as indicated. Replication was monitored by measuring the p24 content of the supernatant. Experiments
were repeated at least three times; representative experiments are shown.
doi:10.1371/journal.ppat.1002558.g002
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cells [18] were transduced with miR HRP-2 or miR control
vectors, the latter containing a miRNA-hairpin directed against
monomeric red fluorescent protein (DsRed) mRNA [33] (Figure
S7C). Following zeocin selection, single HRP-2 KD (wild-type/
miR HRP-2) and double KD (miR LEDGF/miR HRP-2) cells
showed 20–25% of residual HRP-2 mRNA levels compared to the
control cell lines (wild-type, wild-type/miR control and miR
LEDGF/miR control cells) as determined by qPCR (Figure S4A
and S4C). Loss of HRP-2 protein was corroborated by Western
blot analysis and immunocytochemistry (data not shown). Of note,
LEDGF/p75 levels remained unaffected upon additional HRP-2
KD (data not shown) and growth rates of the respective cell lines
were comparable (Figure S6B and S6C). KD of HRP-2 in wild-
type HeLaP4 cells did not affect multiple round HIV-1 replication
(Figure S4B), confirming previous findings by Llano et al. [6].
LEDGF/p75 KD on the other hand reduced HIV-fLuc
transduction 5-fold (luciferase reporter activity=19.263.5% of
wild-type) (Figure S4D). Additional KD of HRP-2 in LEDGF/
p75-depleted cells diminished HIV-fLuc reporter activity an
additional 3-fold, to 6.362% of control cells (miR LEDGF/miR
control) (Figure S4D). This reduction was accompanied with a 2-
fold decrease in the number of integrated copies (Figure S4E).
Transfection of the cell lines with the plasmid encoding HIV-fLuc
(pHIV-fLuc) did not demonstrate any difference (Figure S4F),
ruling out transcriptional effects upon HRP-2 KD. Next, we
infected double KD (miR LEDGF/miR HRP-2) cells and control
(miR LEDGF/miR control) cells together with wild-type and
LEDGF/p75 back-complemented (LEDGF BC) cells with the
laboratory strain HIVNL4.3 (Figure S4G). Viral replication was
inhibited in miR LEDGF cells and rescued upon LEDGF/p75
back-complementation (Figure S4G, compare wild-type and
LEDGF BC). Additional KD of HRP-2 in LEDGF/p75 depleted
cells (miR LEDGF/miR HRP-2) inhibited viral replication more
than LEDGF/p75 KD alone (miR LEDGF/miR control). The
latter demonstrated a breakthrough around day 30 post infection
(Figure S4G, open diamonds), whereas cells with double KD did
not demonstrate viral breakthrough (Figure S4G, open squares).
Analysis was ended at 48 days post infection. Comparable data
were obtained in HeLaP4 cell lines generated with other LV
constructs (Figure S7B and S7D) using hygromycin B selection or
eGFP sorting (data not shown). The additional block of HIV-1
replication upon HRP-2 KD in LEDGF/p75 depleted cell lines
was also measured by quantifying the number of integrated
proviral copies. At day 39, 45 and 48 post infection the number of
integrated copies was low in double KD (miR LEDGF/miR HRP-
2) cells compared to the control LEDGF/p75 KD (miR LEDGF/
miR control) cells (Figure S4H) with proviruses numbering 0.032
(60.012) and 0.038 (60.012) per RNaseP genomic copy on day 39
and 48 respectively, compared to 1.39 (60.18) and 0.79 (60.23) in
the control LEDGF/p75 KD cell lines. In addition, we quantified
different HIV-1 DNA species at different time points post infection
in wild-type, LEDGF/p75 KD (miR LEDGF/miR control) and
double KD cells (miR LEDGF/miR HRP-2). We observed no
difference in late RT products at 10 hrs post infection (Figure S4I).
The number of 2-LTR circles in LEDGF/p75 KD (miR LEDGF/
miR control) and both LEDGF/p75 and HRP-2 KD (miR
LEDGF/miR HRP-2) cells was elevated compared to wild-type
cells (Figure S4J). Together with the data in the LEDGF/p75 KO
cells, these data indicate that HRP-2 KD blocks HIV-1 at a step
between reverse transcription and integration but only after potent
depletion of LEDGF/p75.
Next, we expanded our findings to relevant T-cell lines, PM1
and SupT1. We generated cell lines with stable KD of LEDGF/
p75, HRP-2 or both, together with their respective controls
(constructs shown in Figure S7B). For PM1 cells KD efficiency was
85–92% for LEDGF/p75 (Figure 4A) and 79–81% for HRP-2
(Figure 4B), for SupT1 cells it amounted to 81–88% for LEDGF/
p75 (Figure 4D) and 75–80% for HRP-2 (Figure 4E). In both cell
lines HRP-2 KD alone did not affect HIV-1 replication, whereas a
clear reduction in HIV-1 replication was observed upon LEDGF/
p75 KD (Figure 4C and 4F, left panel, for PM1 and SupT1
respectively). Consistent with our findings in LEDGF/p75 KO
cells and LEDGF/p75 depleted HeLaP4 cells, also in PM1 and
SupT1 cells, HRP-2 KD in LEDGF/p75 depleted cells further
hampered HIV-1 replication (Figure 4C and 4F, detail panels, for
PM1 and SupT1 respectively).
LEDGINs block residual HIV-1 replication in Nalm
2/2 cells
Recently, we reported a new class of antiretrovirals termed
LEDGINs that bind to the LEDGF/p75 binding pocket of HIV-1
IN and block HIV-1 integration and replication in cell culture
[25]. We assayed their activity in the LEDGF/p75 KO cells. We
challenged Nalm
+/+ and Nalm
+/c cells together with Nalm
2/2
cells with the laboratory strain HIVIIIb in the presence of different
concentrations of LEDGIN 7 [25]. LEDGIN 7 blocked HIV-1
replication in all cell lines in a concentration dependent manner
(Figure 5A and 5C). Similar data were obtained with the
laboratory strain HIVNL4.3 (Figure S5A). The toxicity profile in
Nalm-6 cells corresponded to that elaborated previously in MT4
cells [25]. No significant toxicity was observed in the concentra-
tions used (data not shown). Of note, LEDGINs were also active
against HIV harvested from LEDGF/p75 KO cells (HIV
2/2,
data not shown). RAL served as a positive control, demonstrating
equal inhibition of HIV-1 replication in the different cell lines
(Figure 5B and 5D). Dose response curves (Figure 5E and 5F)
enabled determination of IC50 values, listed in Table S1.
LEDGINs also disrupt the interaction of HIV-1 IN with
HRP-2
We have shown that residual replication of HIV-1 laboratory
strains in LEDGF/p75 KO cells is predominantly mediated by
HRP-2 and that LEDGINs block residual HIV-1 replication in
KO cells. This can be explained by allosteric inhibition of
LEDGINs or by the fact that binding of LEDGINs to the IN-
surface also impedes the interaction with HRP-2 or a combination
of both. We evaluated whether LEDGINs inhibit the HRP-2-IN
interaction in an AlphaScreen assay. Since IN binds HRP-2 via its
IBD (aa 470–593) [12] in vitro, we measured the interaction
between recombinant HIV-1 IN and the C-terminal part of HRP-
Figure 3. Additional HRP-2 KD hampers residual replication in LEDGF/p75 KO cells. Stable HRP-2 KD (miR HRP-2) and control (control)
Nalm
+/+, Nalm
+/c and Nalm
2/2 were generated. (A) HRP-2 mRNA levels were determined by qPCR. (B) In the left panel luciferase activity following
HIV-fLuc transduction is shown. Cells were grown for an additional 10 days to eliminate all non-integrated viral DNA species before total viral DNA
was measured as demonstrated in the right panel. (C,D,E) Stable cell lines were challenged with the laboratory strain HIVNL4.3 at different MOIs (5-
0.05). Replication was monitored by measuring the p24 content of the supernatant. In (F) the number of integrated copies as determined by Alu-
qPCR is shown. In (G) we quantified total viral DNA at 5 days post infection, in the presence of Ritonavir (RIT), added 4 hrs post infection. Average 6
standard deviations are shown from experiments performed at least in triplicate.
doi:10.1371/journal.ppat.1002558.g003
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tagged fusions containing either the C-terminal end of LEDGF/
p75 (aa 325–530) or HRP-2 (aa 448–670). These recombinant
proteins, MBP-LEDGF/p75325–530 and MBP-HRP-2448–670,
bound to His6-IN with apparent KD’s of 6.6 nM (64.6 nM) or
89.8 nM (618.1 nM), respectively (Figure 6A). In line with
previous observations [25], LEDGINs inhibited the IN-
LEDGF325–530 interaction (Figure 6B; IC50=2.6060.99 mM).
LEDGINs also inhibited the IN-HRP-2448–670 interaction, albeit
with a 10-fold lower IC50 (Figure 6B; IC50=0.2360.14 mM). This
Figure 4. HRP-2 KD additionally hampers HIV-1 replication in LEDGF/p75 KD cell lines. Stable LEDGF/p75 and/or HRP-2 KD and control
PM1 and SupT1 cells were generated. In (A) qPCR results for LEDGF/p75 and (B) HRP-2 mRNA expression levels, normalized to RNaseP for PM1 are
shown. Average with standard deviations from experiments in triplicate, are shown. The constructs used, are shown below the graph. (C) Multiple
round HIV-1 replication after challenge with the laboratory strain HIVNL4.3. On the right a detail panel for LEDGF/p75 KD cells is shown. In (D) LEDGF/
p75 and (E) HRP-2 expression levels in SupT1 cells, analogous to (A) and (B) are shown. (F) Multiple round HIV-1 replication in the different SupT1 cells,
analogous to (C), is shown.
doi:10.1371/journal.ppat.1002558.g004
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with MBP-HRP-2448–670 compared to MBP-LEDGF325–530 corre-
lates well with the 13-fold lower affinity of MBP-HRP-2448–670 for
IN, as shown in Figure 6A.
Next, we evaluated whether LEDGINs remain active in
LEDGF/p75 KO HRP-2 KD cells. The residual HIV-1
replication was sensitive to inhibition by LEDGINs (Figure S5E).
Discussion
Since the identification of LEDGF/p75 as a binding partner of
HIV-1 IN in 2003 [1], we and other groups have demonstrated its
importance for HIV-1 replication [3–7,10,11,34,35]. Our current
understanding of the mechanism of action proposes LEDGF/p75
to act as a molecular tether between the lentiviral preintegration
Figure 5. LEDGINs block residual HIV-1 replication in LEDGF/p75 KO cells. Nalm
+/c and Nalm
2/2 cell lines were challenged with HIVIIIb in
the presence of varying concentrations of HIV inhibitors. Supernatant was harvested for p24 ELISA. (A,C) LEDGIN 7 was added at different
concentrations (0 mM, circles; 0.2 mM, squares; 3.5 mM, triangles or 31 mM, triangles pointing downwards). (B,D) Identical conditions were used as
shown in (A,C), but the INSTI raltegravir (RAL) was added at different concentrations (0 mM, circles; 0.002 mM, squares; 0.025 mM, triangles or 0.3 mM,
triangles pointing downwards). (A–D) Averages from duplicate experiments 6 standard deviations are shown. (E) Dose-response curves in Nalm
+/c
and Nalm
2/2 cell lines were generated from p24 ELISA values obtained at day 6 for LEDGIN 7 concentrations of 0 mM, 0.06 mM, 0.2 mM, 0.7 mM,
3.5 mM, 8.9 mM, 31 mM. Data are fitted to a sigmoidal dose-response (variable slope) curve, from which IC50 values were calculated (Table S1). (F) In
analogy with (E), p24 values obtained at day 6 for RAL were plotted to enable determination of IC50. RAL was used in concentrations of 0 mM,
0.002 mM, 0.007 mM, 0.02 mM, 0.08 mM and 0.3 mM.
doi:10.1371/journal.ppat.1002558.g005
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capacity of LEDGF/p75 thereby determines integration site
distribution [2,11,17,18]. Given the methodological restrictions
associated with the RNAi and mouse KO studies of the past, we
decided to investigate the role of LEDGF/p75 in HIV-1
replication by generating a human somatic LEDGF/p75 KO
cell line. A second rationale for this study follows the recent
development of LEDGINs, small molecules that efficiently target
the interaction between HIV-1 IN and LEDGF/p75 by
interaction with the LEDGF/p75 binding pocket in HIV-1 IN
[25]. Since LEDGINs block HIV-1 replication, the interest in the
question whether or not LEDGF/p75 is essential for viral
replication was revived.
Our studies demonstrate that residual HIV-1 replication in
LEDGF/p75 KO cells can be observed using laboratory-adapted
HIV-1 strains (Figure 2A). These observations are reminiscent to
data obtained in LEDGF/p75 KD cell lines [5,6,20], although
important differences can be noticed. First, when clinical HIV-1
isolates were used, we observed sterilizing infections in LEDGF/
p75 KO cells (Figure 2B and 2C). Sterilizing infection has never
been reported with RNAi mediated LEDGF/p75 KD. Although
the effect might be in part explained by a lower infectivity of these
clinical isolates, it emphasizes the importance of LEDGF/p75 for
HIV-1 replication. In addition, LEDGF/p75 KO results in a more
pronounced shift of HIV-1 integration out of RefSeq genes when
compared to control cells (25.7% difference when comparing
LEDGF/p75 KO to control cells; Table S3, see column 8),
whereas integration in LEDGF/p75 KD cells was only moderately
affected (1.6–8.4% compared to control cells, Table S3, see
column 8) [2].
A next application of our KO cell line was the investigation of
the role of HRP-2 in HIV-1 replication. The cellular function of
HRP-2 is currently unknown. Like LEDGF/p75, HRP-2 contains
a PWWP domain at its N-terminus [12,22,36,37] and a basic C-
Figure 6. LEDGINs block the interaction of HIV-1 IN with the IBD of either LEDGF/p75 or HRP-2. (A,B) Interactions between His6-tagged
IN and MBP-LEDGF325–530 or MBP-HRP-2448–670 were assessed using AlphaScreen technology. (A) 10 nM MBP-LEDGF325–530 (circles) or MBP-HRP-
2448–670 (squares) was incubated with various concentrations of IN (2-fold dilutions from 500 to 1.9 nM). Anti-MBP donor and Ni
2+-chelate acceptor
beads were added and the AlphaScreen signal was read on an EnVision Multilabel reader. Boxed data show average apparent KD values 6 S.E.M. for
the IN-MBP-LEDGF325–530 or IN-MBP-HRP-2448–670 interaction as determined from four independent experiments, each performed in duplicate. A
representative experiment is shown. (B) MBP-LEDGF325–530 or MBP-HRP-2448–670 (10 nM) was incubated with IN (500 nM) and various concentrations
of LEDGIN 7 (10, 2, 0.2, 0.02 and 0 mM, the latter plotted as 0.001 mM). Again, beads were added and the plate was read as described. Boxed data
show IC50 values of LEDGIN 7 on the interaction of IN with MBP-LEDGF325–530 or MBP-HRP-2448–670. Average IC50 values 6 standard deviations were
derived from three independent experiments each performed in duplicate. A representative experiment is shown. In (C–F) the homology of LEDGF/
p75IBD and HRP-2IBD and their interaction with IN is shown. (C) Alignment of LEDGF/p75347–429 and HRP-2470–552. Amino acids are colored by type and
secondary structure is depicted on top (a-helices in red). Residues involved in the interaction with IN catalytic core domain are boxed. Alignments
were generated with ClustalW [63] and further visualized in ALINE [64]. (D–F) Cartoon representations of the IN catalytic core domain (CCD) dimer
(pale green and pale yellow) with (D) LEDGIN 6 (sticks, colored by atom), (E) LEDGF/p75IBD (gray) or (F) HRP-2IBD (cyan). Side chains of the crucial
amino acids, mimicked by LEDGINs, i.e. residues I365, D366, L368 of LEDGF/p75, and corresponding HRP-2 residues V488, D489 and P491, are shown
in sticks colored by atom. Structures of LEDGF/p75IBD in complex with IN CCD dimer were taken from PDB ID: 2B4J [65]. HRP-2IBD homology models
were built with MODELLER [66], based upon the same LEDGF/p75IBD – IN CCD dimer structure. The structure of the LEDGIN 6 – IN CCD dimer complex
was taken from PDB ID: 3LPU [25]. All structures were visualized in PyMol (DeLano Scientific LLC, Palo Alto, USA).
doi:10.1371/journal.ppat.1002558.g006
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showed that the homologous IBD region in HRP-2 (amino acids
470–593) interacts with IN [12]. Vanegas and colleagues reported
earlier that HRP-2 overexpression relocated HIV-1 IN from the
cytoplasm to the nucleus in LEDGF/p75 depleted cells [23].
Although HRP-2 was investigated previously as a potential
alternative for LEDGF/p75, no effect in multiple round HIV-1
replication was observed after HRP-2 KD alone or in combination
with LEDGF/p75 KD [6,20,24]. However, these observations
may have been obscured by the remaining LEDGF/p75 after
incomplete RNAi mediated KD. Therefore we revisited the
mechanism of residual replication of HIV-1 laboratory strains in
LEDGF/p75 KO cell lines. We demonstrate that both single
round transduction and multiple round replication is additionally
hampered upon HRP-2 KD in LEDGF/p75 KO cells. HIV-1
engages HRP-2 as an alternative for LEDGF/p75, but this low
affinity IN binding partner (Figure 6A) can only substitute for
LEDGF/p75 after depletion of the latter (Figure 3, 4 and S4),
suggesting a dominant role for LEDGF/p75 over HRP-2. Several
reasons can be proposed. Cherepanov et al. [12] demonstrated
that considerably less IN could be co-immunoprecipitated by
HRP-2 than LEDGF/p75, implying that the IN–HRP-2 interac-
tion is weaker than the IN-LEDGF/p75 interaction. In line with
these observations, Vanegas et al. reported that Flag-LEDGF/p75
but not Flag-HRP-2 co-immunoprecipitated IN from cell lysates
[23]. Here we demonstrate using AlphaScreen technology that the
IBD containing C-terminal end of HRP-2 has an approximately
13-fold lower affinity for HIV-1 IN than the corresponding part in
LEDGF/p75 (Figure 6A). Next, LEDGF/p75 demonstrates a
speckled nuclear localization pattern and binds to mitotic
chromatin. Vanegas et al. demonstrated that contrary to
LEDGF/p75, HRP-2 does not bind to mitotic chromatin [23]
questioning its role as a chromatin-tethering molecule. However,
since LEDGF/p75 KD also affects viral replication in non-
dividing macrophages [20], the binding capacity of LEDGF/p75
to condensed mitotic chromatin might not be relevant for HIV-1
replication.
The preference of HIV-1 to integration in genes [38] is reduced
upon LEDGF/p75 KO corroborating previous observations in
LEDGF/p75 KD cells [2,11,17,18] and underscoring LEDGF/
p75 as the major targeting factor for HIV-1 integration. In line
with this tethering role for LEDGF/p75, chimeras carrying
alternative chromatin binding motifs fused to IBD could retarget
HIV-1 integration [18,39,40]. In addition, De Rijck et al. [41]
demonstrated that the LEDGF/p75 chromatin binding mirrors
HIV-1 integration site distribution. HIV-1 integration in RefSeq
genes remained significantly different from MRC throughout
(P,0.0001) and more directed towards CpG islands in LEDGF/
p75 KO cells. Both observations support the idea of an alternative
targeting mechanism for HIV-1 acting in the absence of LEDGF/
p75. Since additional HRP-2 KD resulted in an additional 2-fold
reduction in integrated copies compared to LEDGF/p75
depletion, HRP-2 is a candidate. The integration site distribution
pattern of HIV-1 derived vectors remained unaltered after
additional HRP-2 KD in LEDGF/p75 KD HEK293T cells [2],
but LEDGF/p75 depletion may have been insufficient in those
experiments.
Apart from LEDGF/p75 and HRP-2, no other human protein
contains a PWWP-domain in conjunction with an IBD. However,
other proteins or protein complexes could take over the tethering
activity in the absence of LEDGF/p75 and HRP-2 by combining
an IBD-like domain with a chromatin-binding function. The IBD
belongs to a family exemplified by the Transcription Factor IIS
(TFIIS) N-terminal domain (InterPro IPR017923 TFIIS_N) ([12]
and based on an updated search using the HHpred algorithm
[42,43]). Sequence comparison of the respective predicted IN-
binding loops of these domains, suggests it is however unlikely that
IN binds to these IBD-like proteins as it does to the IBD of
LEDGF/p75 or HRP-2 (data not shown). Therefore the residual
HIV-1 replication observed in the LEDGF/p75 KO HRP-2 KD
cells may 1) still be HRP-2 mediated since the KD of HRP-2 is not
complete, 2) be mediated by an unknown third cellular cofactor or
complex, or 3) occur independently from cellular cofactors.
The question remains whether HRP-2 is of any importance for
HIV infection in patients? The HRP-2 phenotype only becomes
evident in vitro using laboratory strains and upon strong depletion
or KO of LEDGF/p75. Taking into account the lower affinity of
HRP-2 for HIV-1 IN, interaction likely only takes place in the
complete absence of LEDGF/p75. The LEDGF/p75IBD is highly
conserved within humans and across species [12]. Only a few
SNPs have been identified [44]. Although relative LEDGF/p75
and HRP-2 expression levels still need to be verified in relevant
human cells, to date there is no evidence for LEDGF/p75
depletion in humans and a substituting role of HRP-2 in HIV-1
infection.
Previous reports demonstrated a moderate increase in 2-LTR
circles upon LEDGF/p75 KD [5,6], whereas 2-LTR circles were
not significantly different in LEDGF KO MEFs [11]. In this study,
we observed no clear difference in the number of 2-LTR circles
upon LEDGF/p75 KO. Possibly, the complete absence of
LEDGF/p75 affects other steps besides integration that might
result in reduced nuclear import and circle formation. Alterna-
tively, cellular pathways involved in 2-LTR formation may be
affected. Opposing effects on circle formation by reduced import
and reduced integration may finally result in an equal 2-LTR
circle number. Alternatively, the sensitivity of 2-LTR circle
quantification may be too low to detect a small increase.
In the last part of the manuscript we demonstrate that
LEDGINs block the residual replication observed in LEDGF/
p75 KO cell lines (Figure 5C) and block the interaction in vitro
between HRP-2IBD and IN (Figure 6B). Figure 6D illustrates how
LEDGINs fit in the pocket at the IN core dimer interface.
LEDGINs block the interaction with two interhelical loops of the
IBDs of LEDGF/p75 (Figure 6E) or HRP-2 (Figure 6F). The
inhibition of the interaction with HRP-2 can explain why residual
replication of HIV-1 in LEDGF/p75 KO cells is still sensitive to
LEDGINs. Since LEDGF/p75 has been reported to act as an
allosteric modulator of the IN activity in vitro [1,12,45,46], it is
plausible that inhibition of the LEDGF/p75-IN interaction not
only interferes with its function as a molecular tether but also
results in an allosteric inhibition of IN activity. In fact, inhibition of
in vitro IN activity in the absence of LEDGF/p75 by potent
LEDGINs has been reported [25]. The allosteric mode of
inhibition by LEDGINs can as well explain inhibition of HIV-1
replication in LEDGF/p75 KO HRP-2 KD cells [25]. In vivo both
mechanisms are intrinsically coupled. LEDGINs compete with
LEDGF/p75 as a molecular tether and at the same time interfere
with integrase activities probably by affecting conformational
flexibility in the intasome. Whereas transdominant inhibition of
HIV-1 replication by IBD overexpression [4,35] presumably also
acts through this dual mechanism [46], RNAi-mediated depletion
of LEDGF/p75 likely only affects tethering and/or targeting. We
should however be cautious to translate the results in KO cells to
human patients. Since no individuals without functional LEDGF/
p75 expression have been documented, LEDGINs will always
have to compete with LEDGF/p75 for the IN binding pocket to
inhibit integration.
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few studies used this technology to study the role of cellular
cofactors in virus replication. Previously, the role of cyclophilin A
in HIV replication was confirmed in a human somatic KO cell
line [47] as well as the roles of CBF1 [48] and TB7 [49] in Epstein-
Barr virus replication. Our work supports the value of generating
human KO cell lines for cofactor validation and drug discovery in
general.
Materials and Methods
Cells and culture
Nalm-6 cells, SupT1 cells, obtained from the ATCC (Manassas,
VA) and PM1 cells, a kind gift from Dorothee von Laer (Innsbruck
Medical University, Innsbruck, Austria), were maintained in
RPMI 1640 – GlutaMAX-I (Invitrogen, Merelbeke, Belgium)
supplemented with 8% heat-inactivated fetal calf serum (FCS;
Harlan Sera-Lab Ltd.) and 50 mg/ml gentamycin (Gibco,
Invitrogen). HEK293T cells, obtained from O. Danos (Genethon,
Evry, France), and HeLaP4 cells, a kind gift from Pierre
Charneau, Institut Pasteur, Paris, France, were grown in DMEM
(Invitrogen) supplemented with 5% FCS, 50 mg/ml gentamycin
and 0.5 mg/ml geneticin (Invitrogen). All cells were grown in a
humidified atmosphere with 5% CO2 at 37uC.
Growth kinetics
For growth curve analysis, Nalm-6 cells were seeded at 100,000
in 5 ml of corresponding medium and HeLaP4 cells at 200,000
per well in a 6-well plate. Cell growth was followed on consecutive
days by cytometry (Coulter Z1, Beckmann Coulter). Experiments
were performed in triplicate.
Plasmids
The HIV-based lentiviral transfer plasmid pCHMWS_CD4_
IRES_Bsd encodes the CD4 receptor driven by a human early
cytomegalovirus (CMV) promoter followed by an EMCV internal
ribosomal entry site (IRES) and a blasticidin resistance cassette
(Bsd). The plasmid was generated by PCR amplification of human
CD4 from a T-cell cDNA library using CD4-Fwd and CD4-Rev,
followed by digestion with BamHI and XbaI, and cloning into
pCHMWS_LEDGF_BC_IRES_Bsd [18], digested with BamHI
and SpeI.
The lentiviral transfer plasmids for miRNA-based KD were
generated based on miRNA-R30 as previously described [50,51]
(Table S2). For HRP-2 KD, miR HRP-2 was adapted from the
sequence validated previously [6]. As negative controls a non-
functional, scrambled miRNA30-based short-hairpin sequence
(miR scrambled) and a functional, short-hairpin sequence
targeting the monomeric red fluorescent protein from Discosoma
corallimorpharia, DsRed (miR DsRed) were designed [33]. PCR
fragments were introduced into the XhoI–BamHI sites from a
modified pN3-eGFP plasmid (Clontech, Saint Quentin Yuelines,
France) duplicated and cloned into the XhoI-KpnI sites at the
39 end of the enhanced green fluorescent protein (eGFP) re-
porter cDNA, driven by a Spleen focus forming virus LTR
(SFFV) promoter, resulting in pCSMWS_eGFP_miR_HRP2 and
pCSMWS_eGFP_miR_scrambled. To generate pCSMWS_Zeo_
miR_HRP2, the zeocin resistance cassette (Zeo) was amplified
with primers Zeo-Fwd and Zeo-Rev from pBUD (Invitogen),
digested with NheI-Pfl23II and inserted into the XbaI–Pfl23II
digested pCSMWS_eGFP_miR_HRP2 plasmid. To generate
pCSMWS_Zeo_miR_DsRed, miR_DsRed was cloned into the
XhoI/KpnI digested pCSMWS_Zeo_miR_HRP2 plasmid. To
generate pCSMWS_Hygro_miR_HRP2, the hygromycin B
resistance cassette (Hygro) was amplified using Hygro-Fwd and
Hygro-Rev as primers and pBud (Invitrogen) as a template. The
resulting products were digested ClaI-XhoI and ligated into
pCSMWS_Zeo_miR_HRP2.
For bacterial expression of C-terminal His6-tagged HIV-1 IN
and MBP-tagged-LEDGF325–530, the plasmids pKBIN6H [10]
and pMBP-D325 [4] were used, respectively. To construct pMBP-
HRP-2448–670, the sequence corresponding to aa 448 to 670 of
HRP-2 was PCR amplified with primers HRP2-Fwd, and HRP2-
Rev, using p3xFlagHRP-2 (a kind gift from E. Poeschla) as a
template. The resulting products were digested and ligated into
pMAL-c2E (New England Biolabs Inc., USA). The integrity of all
plasmids was confirmed by DNA sequencing.
Retroviral vector production and transduction
LV production was performed as described earlier [18,52].
Briefly, vesicular stomatitis virus glycoprotein (VSV-G) pseudo-
typed lentiviral vector particles were produced by PEI transfection
in HEK293T cells using the different transfer plasmids. Single
round HIVNL4.3DNefDEnvfLuc (HIV-fLuc) virus was prepared by
co-transfection of HEK293T cells with pNL4-3.LucR–E– (pHIV-
fLuc, National Institutes of Health AIDS Research and Reference
Reagent Program) and pMD.G, that codes for VSV-G.
For lentiviral transduction experiments, Nalm-6 cells were
typically plated at 150,000 cells per well in a 96-well plate and
transduced overnight. After 72 hrs, 50% of cells were reseeded for
luciferase expression quantification and/or FACS analysis. The
remainder was cultured for quantitative PCR and integration site
analysis during at least 10 days to eliminate non-integrated DNA.
HeLaP4 cells were plated at 20,000 cells per well in a 96-well plate
and transduced overnight. After 72 hrs, 50% of cells were
reseeded for luciferase quantification. The remainder was cultured
for quantitative PCR or integration site analysis as described for
Nalm-6 cells.
PSIP1 KO targeting plasmids
Targeting plasmids for generation of PSIP1 KO were designed
and cloned as described previously [27,53] utilizing the MultiSite
Gateway System (Invitrogen) as described [54]. Briefly, a 2.3 and a
2.0 kb fragment for the left and right arms of the targeting
plasmids, respectively, were amplified by genomic PCR using
primers LEDGF/p75 attB4 and LEDGF/p75 attB1 for the left
arm, and primers LEDGF/p75 attB2 and LEDGF/p75 attB3 for
the right arm (Table S2). The resulting fragments were cloned into
pDONR/P4-P1R and pDONR/P2R-P3 via recombination,
resulting in p59-ENTR-left and p39-ENTR-right, respectively.
The fragments p59-ENTR-left, p39-ENTR-right, pDEST DTA-
MLS, and pENTR lox-Puro or pENTR lox-Hygro, were then
ligated using recombination to generate the final targeting
plasmids pTARGET-LEDGF/p75-Hyg and pTARGET-
LEDGF/p75-Puro, respectively.
Generation and validation of LEDGF/p75 KO cell lines
Cell lines were generated as previously described [27]. Briefly,
targeting plasmid was transfected with Nucleofector I (Amaxa,
Inc., Gaithersburg, MD, USA) using 2610
6 Nalm-6 cells and 2 mg
of DNA. At 24 hrs after transfection, cells were seeded into 96-well
plates at 10
3 cells per well, in culture medium supplemented with
either 0.2 mg/ml puromycin (BD BioSciences, San Jose, CA, USA)
or 0.35 mg/ml of hygromycin B (Clontech, Mountain View, CA,
USA). After 2–3 weeks, individual drug resistant colonies were
propagated and analyzed by genomic PCR using primers A and B
or C (Figure 1A), generating a 3272 bp AB-fragment for Nalm
+/c,
Nalm
c/c, Nalm
2/2 and a 3123 bp AC-fragment for Nalm
c/c,
HIV Replication in Human LEDGF/p75 Knockout Cells
PLoS Pathogens | www.plospathogens.org 12 March 2012 | Volume 8 | Issue 3 | e1002558Nalm
2/2 (Figure 1C). Genomic PCR of the targeted region was
performed with primers D and E generating a 1624 bp DE-
fragment in Nalm
+/+, Nalm
+/c and a 288 bp DE-fragment in
Nalm
2/2 (Figure 1C). Targeting efficiency was calculated as the
ratio of the number of cell clones where the LEDGF/p75 allele
was disrupted by homologous recombination to the number of
drug-resistant cell clones (Figure 1B). Sequencing of the genomic
KO region was performed as follows. The PCR fragments
obtained after amplification with primers gFB and gRB spanning
a 1885 bp region around exon 11–14 in wild-type cells or a
571 bp region in KO cells, followed by nested PCR with primers
gFA and gRA resulting in a 1694 bp in wild-type or 380 bp region
in KO cells, were cloned into the pCRII-TOPO plasmid
(Invitrogen, Merelbeke, Belgium) and sequenced with primers
M13-Fwd and M13-Rev (Figure S1A). Total RNA extracted from
KO clones (RNeasy 96 kit, Qiagen) was used for cDNA synthesis
using oligo-dT primers (High capacity cDNA RT kit, Applied
biosystems). Correct recombination was verified at mRNA level
for LEDGF/p52, LEDGF/p75 and truncated LEDGF/p75 by
PCR on cDNA using primers RNA-A and RNA-B for LEDGF/
p52, LEDGF/p75 and LEDGF
KO, RNA-A and RNA-C for
LEDGF/p75 and LEDGF
KO, RNA-A and RNA-D for LEDGF/
p52, resulting in fragments of 245 bp, 1.606 kb or 1.163 kb and
1.011 kb, respectively (Figure S1C). Additionally, the cDNA of the
truncated protein was sequence verified (Figure S1A) as follows: a
PCR product generated by primers d243 and RNA-C, followed by
nested PCR with primers d244 and LEDGF-R-exon15, was
cloned into pCRII-TOPO (Invitrogen) and sequenced with M13-
Fwd and M13-Rev. Primers are listed in Table S2.
Generation of stable CD4 expressing Nalm-6 cell lines
Stable CD4 expressing Nalm-6 cell lines were generated by
transducing wild-type Nalm
+/+, Nalm
+/c cl 31 and Nalm
2/2 cl 1
and cl 2, with the lentiviral vector pCHMWS_CD4_IRES_Bsd
and subsequent selection with blasticidin (3 mg/ml; Invitrogen,
Merelbeke, Belgium). CD4 expression was verified by flow
cytometry using R-Phytoerythrin-conjugated mouse anti-human
CD4 monoclonal antibody (BD pharmigen) according to the
manufacturer’s protocol.
Generation of LEDGF/p75 and HRP-2 KD cell lines
Stable monoclonal LEDGF/p75 KD cells were generated
previously [18]. Additional HRP-2 KD was obtained by
transduction of HeLaP4 wild-type cells and LEDGF/p75 KD
cells with pCSMWS_Zeo_miR_HRP2, pCSMWS_Hygro_
miR_HRP2 or pCSMWS_eGFP_miR_HRP2. Transduced cells
were selected with zeocin (200 mg/ml) or hygromycin B (200 mg/
ml) or by FACS sorting of eGFP positive cells respectively. Control
cell lines were generated likewise by transduction with vectors
encoding pCSMWS_Zeo_miR_DsRed, pCSMWS_eGFP_IRES_
HygroR and pCSMWS_eGFP_miR_scrambled, respectively.
Stable PM1 and SupT1 LEDGF/p75 KD cell lines were
generated with LV, encoding a miRNA cassette targeting
LEDGF/p75 under control of an SFFV promoter (unpublished
data). Additional HRP-2 KD and control PM1, SupT1 and Nalm-
6 cell lines were generated by transducing the cells with vectors
made with pCSMWS_Hygro_miR_HRP2 and pCSMWS_eGFP_
IRES_HygroR, respectively.
Integration site amplification and bioinformatic analysis
Integration sites were amplified by linker-Mediated PCR as
described previously [17,18]. For integration sites to be authentic,
sequences needed a best unique hit when aligned to the human
genome (hg18 draft) using BLAT. The alignment began within
3 bp of the viral long terminal repeat end, and had .98%
sequence identity. Reanalysis of previously obtained integration
sites [2,11,17] was performed in parallel. Statistical methods are
described previously [55]. Integration site counts were compared
using a two-tailed Fisher’s exact test. Analysis was carried out
using Prism 5.0 (GraphPad Software).
Virus strains
The origin of HIVNL4.3 [56] and HIVIIIb has been described
[57]. Clinical isolate #1 was obtained through the AIDS research
and reference reagent program, Division of AIDS, NIAID, NIH:
HIV-1 93TH053 from the UNAIDS network for HIV isolation.
Clinical isolate #2 was obtained through the AIDS research and
reference reagent program, Division of AIDS, NIAID, NIH: HIV-
1 96USSN20 from Drs Ellenberger, P. Sullivan and R.B. Lal [32].
The p24 antigen titer was determined for each virus stock. The
MOI was determined using flow cytometry analysis of intracellular
p24 antigen 24 hrs after infection in control Nalm
+/c cells. Cells
were stained with pycoerythrin-anti-p24 (KC57-RD1; Beckman
Coulter) using the Fix&Perm (Invivogen) cell fixation and cell
permeabilization kit following the manufacturer’s protocol.
HIV-1 infection experiments
HIV-1 infection of Nalm-6 cells was typically performed with
1*10
6 cells in 5 ml of medium with the indicated virus and MOI.
After 6–12 hrs of infection, cells were washed twice with PBS and
resuspended in the initial volume of culture medium. Infection of
HeLaP4 cells was performed as described previously [18]. HIV-1
replication was monitored by quantifying p24 antigen in the
supernatant daily via ELISA (Alliance HIV-1 p24 ELISA kit;
Perkin Elmer). Cells were split 1/6 every 5–6 days if experiments
exceeded 10 days. PM1 and SupT1 cells were infected at 0.01 pg
p24/cell.
PCR amplification and DNA sequencing of the coding
regions of IN
Proviral DNA extraction of infected cells was performed using
the QIAamp blood kit (Qiagen) according to the manufacturer’s
protocol. PCR amplification and sequencing of IN encoding
sequences were done as described previously [58].
Antiviral agents
Zidovudine (AZT) and ritonavir (RIT) were purchased and
raltegravir (MK518) was kindly provided by Tibotec (Mechelen,
Belgium). LEDGIN 7 was synthesized as described [25].
Luciferase activity assay
Cells harvested from a 96-well plate were lysed with 50 ml lysis
buffer (50 mmol/l Tris pH 7.5, 200 mmol/l NaCl, 0.2% NP40,
10% glycerol). The lysate was assayed according to the
manufacturer’s protocol (ONE-Glow; Promega, Madison, WI).
Luciferase activity was normalized for total protein (BCA; Pierce,
Rockford, IL). All conditions were run at least in triplicate in each
experiment.
Transfection of plasmid DNA in HeLaP4 cells
HeLaP4 cells were transfected with pHIV-fLuc using Lipofec-
tamine 2000 (Invitrogen, Merelbeke, Belgium) according to the
manufacturer’s protocol with minor modifications. Briefly, 70,000
cells were seeded in a 96 well plate and transfected after one day
with a mixture of 333 ng DNA and 0.66 ml Lipofetamine 2000 for
4 hrs and washed afterwards twice with PBS. 48 hrs post
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Quantitative PCR
Quantification of LEDGF/p75 mRNA levels was performed as
described previously [18]. Similar settings were used to determine
HRP-2 mRNA levels. HRP-2 primer/probe set: HRP2 s4, HRP2
as4 and HRP2 probe. In all cases, RNaseP was used as
endogenous house-keeping control (TaqMan RNaseP Control
Reagent; Applied Biosystems). All samples were run in triplicate
for 3 minutes at 95uC followed by 50 cycles of 10 seconds at 95uC
and 30 seconds at 55uC. Data were analyzed with iQ5 Optical
System Software (BioRad, Nazareth, Belgium). To quantify the
different HIV-1 DNA species qPCR for total viral DNA, 2-LTR
circles and integrated copies was performed as described [59,60],
with minor modifications. Nalm-6 cells were seeded one day prior
to infection at 2*10
5 cells per ml. After 4 hrs of incubation with
HIV, medium was replaced by RPMI containing 10% FCS.
Quantification of proviral copies as shown in Figure 3G was
performed accordingly, only RIT (at 50 times IC50) was added to
the culture medium after the washing step to ensure only a single
replication cycle could take place and genomic DNA was isolated
after 5 days to dilute all non-integrated forms. Non-infected cells
were incubated in parallel. To quantify the number of integrated
copies as shown in Figure S4H, cells were cultured for 10 days in
medium containing RIT and AZT both at 25 times IC50 following
day 39, 45 or 48, before harvesting genomic DNA. Quantitative
Alu-PCR for quantification of proviral copies was done in two steps
[60]. The first phase amplifies from Alu sequences to U3 sequences
absent in self-inactivating (U3-deleted) HIV-1 vectors using
400 nM AluSINIIfwd, 400 nM qAluRout_SB704. Amplification
conditions were 95uC for 30 sec, 60uC for 40 sec, 72uC for 1 min
30 sec, 613 cycles. The second phase amplifies a nested product
using 300 nM sense primer Q-Alu-F-in, 300 nM antisense Q-Alu-
R-in and 200 nM Alu-probe. PCR conditions were 95uC for
10 sec, 55uC for 30 sec, 650 cycles.
Southern blot analysis
Southern blot analysis was performed as described previously in
[61,62]. Briefly, genomic DNA was digested with BamHI,
separated by electrophoresis on a 0.7% agarose gel and blotted
on positively charged nylon membranes (Biodyne B; Pall Corp.,
Pensacola, FL, USA). The probe covered a 1024 bp genomic
region around exon 10 of PSIP1 and was amplified by PCR using
LPROBE-Fwd and LPROBE-Rev, and labeled with a-
32P-dCTP
(Megaprime DNA labeling system, GE Healthcare, USA). Signals
were detected using autoradiography.
Western blotting
Western blotting was performed as described previously [5].
Briefly, cellular extracts were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. LEDGF was detected using a
purified IgG1 mouse anti-human LEDGF monoclonal antibody
(mAb, C26) (BD Biosciences Pharmingen, San Diego, CA). Equal
loading was verified with b-tubulin (T-4026; Sigma-Aldrich, St
Louis, MO). Visualisation was performed by chemiluminescence
(ECL+; Amersham Biosciences, Uppsala, Sweden).
Production and purification of recombinant proteins
Recombinant HIV-1 IN containing a C-terminal His6 tag was
purified as described previously [10]. LEDGF325–530 and HRP-
2448–670 fragments were expressed in E. coli as maltose binding
protein (MBP) fusions. The purification of pMBP-LEDGF325–530
from BL21(DE3) bacterial cells was done as described previously
[4]. For purification, cells were resuspended in lysis buffer (50 mM
Tris-HCl, pH 7.2, 500 mM NaCl, 5 mM dithiothreitol, 1 mM
EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.1 U/ml DNase).
After complete lysis by ultrasonication, the supernatant was
cleared by centrifugation and recombinant proteins were bound to
amylose resin (New England Biolabs Inc, United Kingdom). The
resin was washed with 20 bed volumes wash buffer (50 mM Tris-
HCl, pH 7.2, 500 mM NaCl, 5 mM dithiothreitol), and the MBP-
tagged proteins were eluted in 1 ml fractions wash buffer
supplemented with 10 mM maltose. The fractions were analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis for
protein content, pooled, and concentrated by dialysis (overnight,
4uC) against storage buffer (50 mM Tris-HCl, pH 7.2, 500 mM
NaCl, 50% (vol/vol) glycerol). All protein concentrations were
measured using the Bradford assay (Bio-Rad).
AlphaScreen
AlphaScreen measurements were performed in a total volume
of 25 mL in 384-well Optiwell microtiter plates (PerkinElmer). All
components were diluted to their desired concentrations in assay
buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2,
0.1% Tween-20 and 0.1% BSA). Anti-MBP coated donor beads
were generated by dialyzing biotin-labelled anti-MBP (Vector
Laboratories) to the assay buffer and incubating 10 nM of this
antibody with the desired amount of Streptavidin donor beads
(PerkinElmer) for 1 h at room temperature. For the KD
determinations, HIV-1 IN-His6 was titrated against a background
of 10 nM MBP-LEDGF325–530 or MBP-HRP-2448–670. This
amount provided minimal binding curve perturbation while
maintaining a good signal-to-noise ratio. When performing IC50
determinations, LEDGIN 7 was titrated against a background of
500 nM IN-His6 and 10 nM MBP-LEDGF325–530 or MBP-
HRP-2448–670. After addition of the proteins and/or compounds,
the plate was incubated for 1 h at 4uC and 20 mg/mL anti-MBP
donor and Ni
2+-chelate acceptor beads (PerkinElmer) were
admixed, bringing the final volume to 25 mL. After 1 h of
incubation at RT, protected from light, the plate was read on an
EnVision Multilabel Reader in AlphaScreen mode (PerkinElmer).
Results were analyzed in Prism 5.0 (GraphPad software) after non-
linear regression with the appropriate equations: one-site specific
binding, taking ligand depletion into account for the KD
measurements and sigmoidal dose-response with variable slope
for the IC50 determination.
Accession numbers
The Genbank (http://www.ncbi.nlm.nih.gov/genbank) acces-
sion numbers for the proteins discussed in this paper are LEDGF/
p52 (NM_021144.3), LEDGF/p75 (NM_033222.3) and HRP-2
(NM_032631.2).
Supporting Information
Figure S1 Characterization of LEDGF/p75 KO cells. (A)
Scheme of LEDGF/p75, LEDGF/p52 and the truncated variant
of LEDGF/p75 after proficient KO (LEDGF
KO). Different
domains of LEDGF are shown: PWWP-domain, nuclear locali-
zation signal (NLS), AT-hook like domains (AT-hooks) and the
IBD. The sequencing product of the mRNA of LEDGF
KO in the
KO clones reveals the predicted frame shift after joining of exon
10 and 15, leading towards a premature stop codon. (B) Scheme of
mRNA transcripts of LEDGF/p52 and LEDGF/p75. The KO
region is indicated with a horizontal red bar. (C) Analysis of
mRNA with reverse transcriptase PCR (RT-PCR), indicated
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LEDGF/p75 mRNA was evaluated with quantitative reverse
transcriptase PCR (qRT-PCR), normalized for RNaseP expression
levels and depicted relative to wild-type levels. Primer E and F
used are depicted in B. Average 6 standard deviations are shown
from experiments performed at least in triplicate. (E–F) Analysis of
HIV-1 DNA species in Nalm
+/c and Nalm
2/2 cell lines at
different time points after infection with single round HIV-fLuc.
(E) Relative number of total viral cDNA transcripts and (F) 2-LTR
circles. Experiments were performed in duplicate and analyzed
with qPCR in triplicate. Copy number ratio normalized to
RNaseP of a representative experiment is shown with standard
deviations. (G–H) HIV-1 integration site distribution analysis.
Relative number of experimentally derived HIV-1 integration
events in genes according to the Ensembl (G) and UniGene (H)
annotation, versus computationally generated matched random
controls (MRC). (I–J) Integration site consensus at sequences
flanking HIV-1 proviruses in control and LEDGF/p75 KO Nalm-
6 cells is shown. (I) HIV-1 in Nalm
+/c, (J) HIV-1 in Nalm
2/2 (data
from Nalm
2/2 cl 1 and 2 were pooled). The diagrams were
generated using the WebLOGO program (weblogo.berkeley.edu/
logo.cgi). The y-axis indicates bits of information with a perfect
conservation of a base scoring as two bits.
(EPS)
Figure S2 Characterization of spreading infection in
LEDGF/p75 KO cells. (A) Control Nalm
+/+ and Nalm
+/c and
KO Nalm
2/2 cl 1 and cl 2 cell lines, were challenged with a
laboratory strain HIVNL4.3 virus. Cells were infected at different
MOI as indicated in the graph. (B) Control Nalm
+/c and Nalm
2/2
cl 2 cells were challenged with the laboratory strain HIVNL4.3.
Cells were washed after 8 hrs (arrow) and resuspended in medium
with or without inhibitors. The gray line above the chart indicates
the duration of treatment. AZT and RIT were used at 50 times
IC50. Mean with standard deviations of experiments performed in
duplicate are shown. Replication was monitored by measuring the
p24 content in the supernatant. (C) Nalm
+/c and KO Nalm
2/2 cl
1 cells were challenged with HIV
+/c (C, left panel) and HIV
2/2
(C, right panel). Values from three independent experiments were
each normalized to the peak p24 amount, consistently observed in
Nalm
+/c at day 6. Mean relative p24 amount in Nalm
2/2 at day
15 after challenge with HIV
+/c was 7.45%66.8 and 7.20%64.0
after challenge with HIV
2/2.
(EPS)
Figure S3 Analysis of HIV-1 DNA species in Nalm
+/c
and Nalm
2/2 cell lines at different time points after
infection with HIVNL4.3. (A) Relative number of total viral
DNA, (B) 2-LTR circles and (C) integrated proviral copies (Alu-
qPCR). Experiments performed in duplicate and analyzed with
qPCR in triplicate. Copy number ratio normalized to RNaseP of a
representative experiment is shown with standard deviations. RAL
was used at 50 times IC50 concentration.
(TIF)
Figure S4 Additional HRP-2 KD blocks residual HIV-1
replication in LEDGF/p75 KD cells. (A–B) Multiple round
HIV-1 replication in HeLaP4 HRP-2 KD cells (wild-type miR
HRP-2) and control cell lines (wild-type and wild-type miR
control). (A) HRP-2 mRNA levels were determined by qPCR,
normalized to RNaseP expression levels and expressed as
percentage from wild-type. (B) Cells were challenged with
HIVNL4.3 and supernatant was harvested for p24 ELISA.
Experiments were performed in duplicate; a representative
experiment is shown. (C–J) Additional HRP-2 KD (miR
LEDGF/miR HRP-2) and control (miR LEDGF/miR control)
cell lines were generated from stable LEDGF/p75 KD HeLaP4
cell lines (miR LEDGF). Constructs used to generate the cells are
listed below the graph. (C) HRP-2 mRNA expression levels were
determined with qPCR, normalized to RNaseP expression levels
and expressed as percentage from wild-type. (D) Different cell lines
were transduced with HIV-fLuc and luciferase expression was
quantified (RLU per mg protein). In (E) the number of integrated
copies was determined. Following transduction with HIV-fLuc,
cells were grown for an additional 10 days to eliminate non-
integrated viral DNA. (F) Different HeLaP4 cell lines were
transfected with pHIV-fLuc and luciferase expression was
quantified. In panel (G) we challenged the different cell lines with
the laboratory strain HIVNL4.3. The experiment was continued for
48 days. Supernatant was harvested for p24 ELISA. Experiments
were performed in duplicate; a representative experiment is
shown. (H) Following multiple round HIV-1 infection as presented
in (G), we determined the number of proviral copies by qPCR in
miR LEDGF/miR control and miR LEDGF/miR HRP-2 cells on
day 39, 45 and 48, when cells were grown for an additional 10
days in the presence of antiretroviral therapy to eliminate non-
integrated viral DNA. In (I) we determined late reverse transcripts
(Late RT products) at 10 hrs post infection (p.i.) with HIVNL4.3
using qPCR, normalized to RNaseP genomic copies. In (J) 2-LTR
circles were determined at 24 hrs post infection with HIVNL4.3
using qPCR, normalized to RNaseP genomic copies. Average 6
standard deviations are shown from experiments performed at
least in triplicate.
(TIF)
Figure S5 Effect of LEDGINs on HIV in LEDGF/p75 KO
HRP-2 KD cells. (A) Control Nalm
+/c and KO Nalm
2/2 cell
lines were challenged with the laboratory strain HIVNL4.3 in the
absence (0 mM) or presence of LEDGIN 7 (31 mM). Experiments
were performed in duplicate; average 6 standard deviations is
shown. (B–E) Stable HRP-2 KD (miR HRP-2) and control
(control) Nalm
+/c and Nalm
2/2 cells were challenged with
HIVIIIb in the presence of various concentrations of LEDGIN 7
(0 mM, circles; 0.2 mM, squares; 2.5 mM, triangles or 31 mM,
triangles pointing downwards). (F) Luciferase activity following
HIV-fLuc transduction in the different cell lines is shown. Average
6 standard deviations is shown from experiments performed in
triplicate. Replication was monitored by measuring the p24
content of the supernatant.
(EPS)
Figure S6 Cell growth and expression levels of CD4 or
CXCR4. (A) On day zero 100,000 Nalm-6 cells were seeded in
triplicate in 5 ml of culture medium. Cells were counted on a daily
basis. Average numbers and standard deviations are shown. (B)
Different HeLaP4 cell lines were seeded at 200,000 cells in a 6 well
format and counted daily. Average and standard deviations of
experiments in triplicate are shown. The different vectors used to
generate the additional HRP-2 KD-control cel lines are specified
within brackets. In (C) the doubling time and 95% confidence
interval (95% CI) was calculated after nonlinear regression
(exponential growth curve fit). The representing R-square (R
2)i s
given. (D) Stable CD4-expressing cell lines selected with blasticidin
were generated through transduction with a lentiviral vector
(pCHMWS_CD4_IRES_Bsd). Equal expression was verified with
flow cytometry using a PE-labeled CD4 antibody. Experiments
were performed in triplicate, averages of percentage gated cells
times MFI and standard deviation are shown. Nalm
+/+, Nalm
+/c,
Nalm
2/2 cl 1 and cl 2 used in this figure represent CD4-
expressing descendants from Nalm-6 cell lines as described in
Figure 1. (E) Nalm-6 cells express the HIV-1 coreceptor CXCR4
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with flow cytometry using a PE-labeled CXCR4 antibody.
(EPS)
Figure S7 Schematic overview of viral vector constructs.
(A) Lentiviral vector construct for CD4 expression. (B–D) Different
lentiviral vectors to generate stable HRP-2 KD and control cell
lines, ordered pairwise, are shown. Abbreviations: IRES, internal
ribosomal entry site; Hygro, hygromycin B; HRP-2, Hepatoma
derived growth factor related protein 2; Bsd, blasticidin; Zeo,
zeocin.
(EPS)
Table S1 IC50 values for LEDGINs (LEDGIN 7) and
INSTIs (RAL). IC50 values for LEDGIN 7 and Raltegravir were
calculated based on data shown in figure 6. Data were fitted to a
sigmoidal dose-response (variable slope) curve, from which IC50
values were calculated. Mean and 95% confidence interval are
shown.
(DOC)
Table S2 Overview of primers and probes used. Primers
and probes used throughout the manuscript are shown.
(DOC)
Table S3 Effect of LEDGF/p75 KD or KO on the
frequency of viral integration in genomic features.
Comparison of the HIV integration site distribution pattern
elaborated in current and previous publications [2,11,17].
Frequency of viral integration in genomic features (integration in
RefSeq genes, 62k bo r64 kb around CpG islands) is shown.
(DOC)
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